# Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

> **NCT04925193** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Pomalidomide
- **DRUG:** Daratumumab
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04925193
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2024-08-06
- **Final completion:** 2026-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925193, "Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04925193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*